Skip to main content

Table 5 Multivariate analyses

From: Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

  Chronic GVHD NRM Relapse LFS OS GRFS
p value OR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI)
In vivo T cell depletion 0.0001 0.46 (0.31–0.68) 0.094 0.59 (0.32–1.09) 0.149 0.72 (0.46–1.12) 0.027 0.67 (0.46–0.95) 0.027 0.65 (0.44–0.95) 4 × 10−5 0.51 (0.37–0.70)
Age at SCT >50 years 0.447 1.13 (0.82–1.57) 0.012 1.83 (1.14–2.94) 0.083 1.39 (0.96–2.00) 0.004 1.53 (1.15–2.05) 0.026 1.42 (1.04–1.93) 0.037 1.32 (1.02–1.71)
Interval diag. to SCTa 0.465 1.05 (0.91–1.22) 0.209 1.00 (1.00–1.00) 0.974 1.00 (1.00–1.00) 0.461 1.00 (1.00–1.00) 0.410 1.00 (1.00–1.00) 0.717 1.00 (1.00–1.00)
Year of SCT 0.929 1.00 (1.00–1.00) 0.894 0.99 (0.87–1.30) 0.862 1.01 (0.91–1.12) 0.960 1.00 (0.92–1.09) 0.558 0.98 (0.90–1.06) 0.522 0.98 (0.91–1.05)
Secondary AML 0.033 1.68 (1.04–2.72) 0.232 1.55 (0.76–3.19) 0.434 1.26 (0.71–2.26) 0.192 1.35 (0.86–2.12) 0.163 1.40 (0.87–2.25) 0.058 1.47 (0.99–2.18)
Female D to male R 0.001 1.75 (1.27–2.43) 0.669 1.12 (0.66–1.90) 0.319 1.22 (0.82–1.82) 0.306 1.18 (0.86–1.62) 0.253 1.21 (0.87–1.69) 0.0004 1.62 (1.24–2.11)
R CMV seropositivity 0.231 1.32 (0.84–2.09) 0.851 0.93 (0.46–1.90) 0.733 0.91 (0.55–1.53) 0.651 0.91 (0.60–1.38) 0.456 0.85 (0.55–1.31) 0.639 0.92 (0.64–1.32)
D CMV seropositivity 0.417 1.17 (0.81–1.68) 0.241 1.49 (0.77–2.89) 0.812 1.06 (0.67–1.68) 0.358 1. 20 (0.82–1.75) 0.359 1.21 (0.81–1.80) 0.832 1.04 (0.75–1.42)
Center (frailty variable) 0.0007   0.047   0.211   0.917   0.913   0.154  
  1. AML acute myeloid leukemia, CMV cytomegalovirus, D donor, diag diagnosis, GRFS GVHD/relapse-free survival, GVHD graft-versus-host disease, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, R recipient, SCT allogeneic stem cell transplantation
  2. aAnalyzed per 6-month interval